生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139 生物科技

交易中 04-08 11:27:56 EDT

1,123.10

+17.08

+1.54%

最高1,126.17	最低1,106.03	成交量10.83亿
今开1,106.03	昨收1,106.02	日振幅1.82%
总市值0.00	流通市值0.00	总股本0.00
成交额40.56亿	换手率--	流通股本0.00
市净率6.77937	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1123.0974,"timestamp":1775662076034,"preClose":1106.0168,"halted":0,"volume":1083198843,"delay":0,"changeRate":0.015443,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":17.080566,"latestTime":"04-08 11:27:56 EDT","open":1106.0312,"high":1126.1693,"low":1106.0312,"amount":4056490748.637329,"amplitude":0.018208,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1775678400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.77937,"peRate":-208.990902,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"1119491727","title":"MAIA Biotechnology预计近期3300万美元融资将全额资助新型端粒靶向抗癌疗法关键三期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1119491727","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119491727?lang=zh_cn&edition=full","pubTime":"2026-04-08 21:02","pubTimestamp":1775653346,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology公司宣布，近期完成的3300万美元融资预计将完全覆盖其创新端粒靶向抗癌疗法的关键性三期临床试验费用。\n这项融资将确保公司核心研发项目获得充足资金支持，推动新型抗癌药物的临床进展。该疗法通过靶向端粒机制抑制癌细胞增殖，目前正处于临床试验的关键阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186367824","title":"Cue Biopharma将获得勃林格殷格翰合作与授权协议项下750万美元临床前里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1186367824","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186367824?lang=zh_cn&edition=full","pubTime":"2026-04-08 20:00","pubTimestamp":1775649634,"startTime":"0","endTime":"0","summary":"Cue Biopharma, Inc. (以下简称Cue Biopharma) 宣布，其与勃林格殷格翰达成的合作与授权协议已达成一项重要临床前里程碑。根据协议条款，Cue Biopharma将因此获得750万美元的付款。\n该笔款项的支付标志着双方在特定药物研发项目上取得了关键进展，体现了合作关系的稳步推进。此次里程碑的达成不仅为Cue Biopharma带来了即时资金支持，也进一步验证了其技术平台在药物发现阶段的潜力。\n双方将继续推进合作项目的后续开发工作，致力于将创新疗法推向市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189405805","title":"Opko Health旗下Modex Therapeutics启动MDX2301预防新冠临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1189405805","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189405805?lang=zh_cn&edition=full","pubTime":"2026-04-08 20:00","pubTimestamp":1775649631,"startTime":"0","endTime":"0","summary":"Opko Health子公司Modex Therapeutics已正式启动MDX2301的临床试验，该药物旨在用于新冠病毒的预防。此次试验标志着公司在抗病毒治疗领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4196","OPK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625314946","title":"再生元 2025 年全年营收143.43亿美元  2026年研发费用预计最高达66.8亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2625314946","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625314946?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:53","pubTimestamp":1775649198,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再生元制药 公布 2025 年第四季度及全年财务业绩。Q4 总收入 38.84 亿美元，同比增长 3%；全年总收入 143.43 亿美元，同比增长 1%。全年 GAAP 净利润 45.05 亿美元，同比增长 2%；GAAP 摊薄每股收益 41.48 美元，同比提升 8%。研发投入持续加码，2025 年研发费用 58.50 亿美元，同比增长 14%，DB-OTO、garetosmab 等重点品种预计 2026 年获批上市。公司同时发布 2026 年业绩指引：GAAP 研发费用预计 64.50 亿 - 66.80 亿美元，销售管理费用 28.60 亿 - 30.40 亿美元，产品毛利率 79%-80%，资本开支 11.00 亿 - 13.00 亿美元。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/ODQyMGE4ZDAyNTIxMTM1NjQzNTI0MDc=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODQyMGE4ZDAyNTIxMTM1NjQzNTI0MDc=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298910","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","LU2468319806.SGD","LU2237438978.USD","BK4588","LU0289739699.SGD","LU2362541513.USD","LU0114720955.EUR","LU2089984988.USD","LU0823416689.USD","BK4585","LU1974910355.USD","LU0109394709.USD","LU2362540622.SGD","LU0320765992.SGD","LU0823434583.USD","LU1917777945.USD","LU0889565916.HKD","LU0823434740.USD","LU2362541273.HKD","LU0058720904.USD","LU0053666078.USD","BK4139","REGN","LU2023250504.SGD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127842530","title":"Plus Therapeutics公司Reyobiq™获美国FDA儿科恶性胶质瘤孤儿药认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1127842530","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127842530?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:30","pubTimestamp":1775647814,"startTime":"0","endTime":"0","summary":"Plus Therapeutics公司近日宣布，其研发的药物Reyobiq™已获得美国食品药品监督管理局（FDA）授予的孤儿药认定，用于治疗儿科恶性胶质瘤。这一认定有望加速该药物在罕见儿科疾病领域的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145598359","title":"再生元制药公司预计2026年第一季度将录得1.02亿美元税前IPR&D费用","url":"https://stock-news.laohu8.com/highlight/detail?id=1145598359","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145598359?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:08","pubTimestamp":1775646498,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件，再生元制药公司披露，预计在2026年第一季度将产生一笔高达1.02亿美元的税前费用。\n此项费用将同时按照美国通用会计准则（GAAP）和非美国通用会计准则（Non-GAAP）进行列报，涉及的是IPR&D项目。IPR&D，即“已购入进程研发”，通常指企业在并购过程中获得的、尚未完成商业准备的研发项目资产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","BK4585","LU2089984988.USD","LU0823434583.USD","BK4588","LU2237438978.USD","LU2362541273.HKD","LU2106854487.HKD","LU0058720904.USD","LU2468319806.SGD","LU0320765992.SGD","LU0823416689.USD","BK4139","LU2362541513.USD","LU0114720955.EUR","LU1974910355.USD","LU2362540622.SGD","REGN","LU0823434740.USD","LU0889565916.HKD","LU0109394709.USD","LU0289739699.SGD","LU2023250504.SGD","LU0882574055.USD","LU1917777945.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159418166","title":"美国联合医疗Miroliverelap®获FDA再生医学先进疗法认定，用于急性肝衰竭治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1159418166","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159418166?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:03","pubTimestamp":1775646225,"startTime":"0","endTime":"0","summary":"美国联合医疗（United Therapeutics）宣布，其研发的药物Miroliverelap®已获得美国食品药品监督管理局（FDA）授予的再生医学先进疗法（RMAT）认定，适应症为急性肝衰竭。这一认定将加速该疗法的开发和审评进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1699723380.USD","UTHR","LU1571399168.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138462511","title":"诺瓦瓦克斯医药盘前股价飙升6.1%；维权投资者Shah Capital宣布将投票反对公司高管薪酬及董事提名","url":"https://stock-news.laohu8.com/highlight/detail?id=1138462511","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138462511?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:07","pubTimestamp":1775642839,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药（NVAX）股价在盘前交易时段大幅上涨6.1%，引发市场关注。与此同时，知名维权投资机构Shah Capital公开表示，将在公司即将举行的股东大会上对高管薪酬方案及董事会候选人名单投下反对票。\n这一股价异动与股东积极行动同时出现，凸显了市场对诺瓦瓦克斯医药公司治理状况的高度关注。Shah Capital作为长期关注公司治理的活跃投资者，此次采取反对立场可能影响其他机构投资者的投票决策。\n目前，诺瓦瓦克斯医药尚未就此事发表官方评论。市场分析师指出，此类股东行动通常反映了投资者对公司战略方向或管理层表现的不满，可能促使公司重新评估其治理结构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BK4139","BK4547","BK4585","BK4568","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185735364","title":"Shah Capital敦促诺瓦瓦克斯医药赎回2.25亿美元可转债及/或启动1000万至2000万股回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1185735364","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185735364?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:00","pubTimestamp":1775642419,"startTime":"0","endTime":"0","summary":"知名投资机构Shah Capital近日公开呼吁生物技术公司诺瓦瓦克斯医药采取积极资本管理措施，建议其尽快赎回市场上流通的2.25亿美元可转换债券，同时考虑启动规模达1000万至2000万股的股票回购计划。通过削减债务规模和回购股份，诺瓦瓦克斯医药有望优化资本结构，进一步提升每股收益指标。值得注意的是，诺瓦瓦克斯医药作为疫苗研发领域的重要参与者，其资本运作动向备受关注。Shah Capital的建议若被采纳，可能引发连锁市场反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4547","BK4585","BK4568","NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625128969","title":"百济神州(06160)授出合共1.77万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2625128969","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625128969?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:27","pubTimestamp":1775640476,"startTime":"0","endTime":"0","summary":"百济神州(06160)发布公告，于2026年3月31日，董事会薪酬委员会根据2016期权及激励计划的条款授予154名承授人合共1.77万股美国存托股份受限制股份单位。该等受限制股份单位相当于22.98万股股份，约占本公告之日公司发行股份总数的0.01%。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_23.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_23.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1719994722.HKD","LU1969619763.USD","688235","LU1251922891.USD","06160","BK4139","BK1161","ONC","BK4588","BK1583","BK1588","LU0307460666.USD","BK0239","BK4526","LU1303224171.USD","BK4585","LU1770034418.SGD","BK1500","LU0588546209.SGD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183859739","title":"Equillium Inc. 股东售股计划：包含可行使预融资权证发行的1770万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1183859739","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183859739?lang=zh_cn&edition=full","pubTime":"2026-04-08 05:17","pubTimestamp":1775596630,"startTime":"0","endTime":"0","summary":"Equillium Inc. 宣布其股东售股计划中，包含一项重要条款：通过行使预融资权证，可发行高达1770万股的公司普通股。这一安排为股票的潜在增发提供了明确路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EQ","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135444894","title":"Insmed研究未达主要及次要疗效终点 公司将终止HS项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1135444894","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135444894?lang=zh_cn&edition=full","pubTime":"2026-04-08 04:02","pubTimestamp":1775592132,"startTime":"0","endTime":"0","summary":"Insmed公司宣布，其最新研究未能达到预设的主要疗效终点和次要疗效终点指标。基于这一结果，公司决定终止HS项目的后续开发。\n该临床试验结果的公布，意味着Insmed在相关治疗领域的探索暂告一段落。公司表示将继续评估其他研发管线的进展，优化资源分配。\n此次研究数据的披露，为投资者和行业观察者提供了该公司研发进展的重要参考依据。市场将密切关注Insmed后续的战略调整和管线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","LU0320765992.SGD","LU0109394709.USD","INSM","LU0889565916.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130614255","title":"吉利德科学再度出手收购癌症药物合作伙伴——市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1130614255","media":"投资观察","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130614255?lang=zh_cn&edition=full","pubTime":"2026-04-07 22:26","pubTimestamp":1775572014,"startTime":"0","endTime":"0","summary":"吉利德科学公司再度出手收购其癌症药物合作伙伴，该公司已达成协议，将以最高50亿美元的价格收购Tubulis公司。今年二月，吉利德宣布将收购ARCELLX, INC.的全部剩余股份，该公司是吉利德在开发针对多发性骨髓瘤这一血癌的潜在CAR-T细胞疗法方面的合作伙伴，该交易对这家生物技术公司的估值在交易完成时约为78亿美元。\nRBC资本市场的分析师指出，此次收购Tubulis是一项战略上合理的补充性收购，既能满足吉利德肿瘤学产品管线增长的需求，又能确保获得差异化的下一代抗体偶联药物平台能力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU0882574055.USD","LU2087621335.USD","LU0109394709.USD","LU0965509283.SGD","LU0965508806.USD","LU2089984988.USD","LU2468319806.SGD","BK4568","LU0823416689.USD","BK4585","LU1057294990.SGD","LU1061106388.HKD","BK4550","LU1839511570.USD","LU0114720955.EUR","SG9999015986.USD","LU1037948897.HKD","LU1674673428.USD","LU0861579265.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE0002270589.USD","LU1674673691.USD","LU1066053197.SGD","LU1934455194.USD","LU1571399168.USD","LU2324357040.USD","LU0320765992.SGD","BK4583","BK4566","LU1430594728.SGD","SG9999015978.USD","IE00BZ1G4Q59.USD","SG9999015952.SGD","LU1066051498.USD","BK4532","LU0058720904.USD","IE00B3T34201.USD","LU0965509101.SGD","LU1934455277.USD","BK4578","LU2112291526.USD","BK4139","LU1934455863.HKD","GILD","LU1023059063.AUD","SG9999015945.SGD","LU1778281490.HKD","LU0289739699.SGD","LU0965509010.AUD","IE00B19Z3581.USD","LU0234570918.USD","LU1037948541.HKD","LU1585245621.USD","BK4588","ACLX","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625303955","title":"50亿美元掷向ADC赛道，吉利德科学(GILD.US)高价收购德国Tubulis","url":"https://stock-news.laohu8.com/highlight/detail?id=2625303955","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625303955?lang=zh_cn&edition=full","pubTime":"2026-04-07 21:15","pubTimestamp":1775567710,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，吉利德科学同意收购德国私营生物技术公司 Tubulis GmbH，交易总价值高达 50 亿美元。吉利德目前已经销售一种名为 Trodelvy 的乳腺癌 ADC 药物。Tubulis 正在针对卵巢癌、肺癌以及其他类型的肿瘤进行药物临床试验。数据显示，卵巢癌市场到 2030 年的价值可能达到 56 亿美元，Tubulis 在该领域有潜力挑战阿斯利和礼来等巨头。这是吉利德今年以来的第三笔重大交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0965508806.USD","LU0823416689.USD","LU2112291526.USD","GILD","LU0965509101.SGD","IE00B3T34201.USD","LU2089984988.USD","LU1585245621.USD","LU1934455194.USD","SG9999015986.USD","LU0965509010.AUD","ADC","LU0889565916.HKD","LU1037948541.HKD","IE00BZ1G4Q59.USD","BK4532","LU0320765992.SGD","FDAXmain","IE00BSNM7G36.USD","LU1057294990.SGD","FDXSmain","LU0234570918.USD","LU0861579265.USD","BK4550","LU1023059063.AUD","LU1934455277.USD","LU2468319806.SGD","BK4566","LU0122379950.USD","BK4583","LU1061106388.HKD","SG9999015978.USD","BK4568","LU2324357040.USD","BK4231","LU0882574055.USD","IE00B19Z3B42.SGD","BK4578","BK4588","IE00BKVL7J92.USD","LU0965509283.SGD","LU1066053197.SGD","FDXMmain","IE0002270589.USD","LU0289739699.SGD","LU1674673691.USD","LU0114720955.EUR","BK4139","LU1839511570.USD","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155608590","title":"阿卡迪亚制药宣布Daybue® Stix（曲非奈肽）现已在美国全面上市，用于治疗雷特综合征","url":"https://stock-news.laohu8.com/highlight/detail?id=1155608590","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155608590?lang=zh_cn&edition=full","pubTime":"2026-04-07 21:05","pubTimestamp":1775567111,"startTime":"0","endTime":"0","summary":"阿卡迪亚制药（ACADIA Pharmaceuticals）正式宣布，其用于治疗雷特综合征的药物Daybue® Stix（曲非奈肽）目前在美国市场已实现广泛供应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU2065171402.SGD","LU2065169927.USD","LU2065170008.USD","BK4139","ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164642417","title":"Outlook Therapeutics宣布FDA已受理关于Ons-5010/Lytenava™（贝伐珠单抗-Vikg）的正式争议解决申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1164642417","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164642417?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:50","pubTimestamp":1775566215,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.披露，美国食品药品监督管理局（FDA）已正式接受该公司针对其核心候选药物Ons-5010/Lytenava™（贝伐珠单抗-Vikg）所提交的正式争议解决请求。这一进展标志着公司在推动该眼科疗法获批的进程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109962795","title":"吉利德科学将收购Tubulis，引入潜在同类最佳抗体偶联药物及新一代平台，进一步强化肿瘤产品管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1109962795","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109962795?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:31","pubTimestamp":1775565084,"startTime":"0","endTime":"0","summary":"吉利德科学宣布收购Tubulis公司，此举将为公司带来潜在同类最优的抗体偶联药物以及新一代技术平台，从而显著增强其在肿瘤治疗领域的产品管线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","SG9999015952.SGD","LU0965509283.SGD","LU0289739699.SGD","LU2089984988.USD","LU1430594728.SGD","IE00BSNM7G36.USD","LU1037948897.HKD","LU1037948541.HKD","LU0109394709.USD","LU1066053197.SGD","BK4568","LU1934455863.HKD","LU1023059063.AUD","LU2324357040.USD","BK4583","IE00BZ1G4Q59.USD","LU1571399168.USD","LU0320765992.SGD","IE00B19Z3581.USD","LU1061106388.HKD","LU1778281490.HKD","IE0002270589.USD","LU0882574055.USD","IE00B19Z3B42.SGD","LU1839511570.USD","LU1585245621.USD","GILD","BK4566","LU2468319806.SGD","LU1674673428.USD","LU2112291526.USD","SG9999015978.USD","LU0861579265.USD","LU0234570918.USD","SG9999015945.SGD","BK4550","LU1674673691.USD","BK4532","BK4585","IE00B3T34201.USD","LU0965508806.USD","LU1934455194.USD","LU0122379950.USD","LU0114720955.EUR","LU0058720904.USD","LU1934455277.USD","LU0823416689.USD","LU1066051498.USD","LU0889565916.HKD","LU1057294990.SGD","BK4578","LU0965509010.AUD","LU0965509101.SGD","LU2087621335.USD","SG9999015986.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156303425","title":"Piper Sandler将Soleno Therapeutics评级从增持下调至中性，目标价从145美元大幅削减至53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156303425","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156303425?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:25","pubTimestamp":1775564715,"startTime":"0","endTime":"0","summary":"Piper Sandler宣布，将生物制药公司Soleno Therapeutics的股票评级从\"增持\"下调至\"中性\"。同时，该机构将其目标股价从145美元大幅下调至53美元，显示出对公司短期前景的谨慎态度。此次评级和目标价的双重调整，可能影响市场对该股的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176735830","title":"Savara宣布英国MHRA受理Molgradex治疗自身免疫性肺泡蛋白沉积症的上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1176735830","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176735830?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:21","pubTimestamp":1775564504,"startTime":"0","endTime":"0","summary":"Savara Inc宣布，英国药品和保健品管理局（MHRA）已正式受理其药物Molgradex用于治疗自身免疫性肺泡蛋白沉积症的上市许可申请。\n根据公司披露的时间表，MHRA对Molgradex上市许可申请的决定预计将在2026年第四季度公布。与此同时，美国食品药品监督管理局（FDA）针对Molgradex生物制品许可申请设定的处方药用户付费法案目标日期为2026年8月22日。此外，欧洲药品管理局人用药品委员会对Molgradex上市许可申请的决定预计将于2027年第一季度作出。\n","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111294591","title":"吉利德科学将以31.5亿美元现金预付款收购Tubulis，潜在里程碑金额高达18.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111294591","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111294591?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:19","pubTimestamp":1775564350,"startTime":"0","endTime":"0","summary":"生物制药巨头吉利德科学宣布达成一项重大收购协议，将以31.5亿美元现金作为预付款，收购专注于抗体偶联药物研发的德国生物技术公司Tubulis。根据协议条款，若Tubulis在后续研发中达成特定里程碑，吉利德还将额外支付最高18.5亿美元的资金。此次交易凸显了吉利德科学在肿瘤治疗领域的战略布局。协议设计的里程碑付款机制，既体现了吉利德对Tubulis技术潜力的认可，也显示出其对研发成果的审慎评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","GILD","LU1066053197.SGD","LU1585245621.USD","LU0289739699.SGD","IE00B7SZLL34.SGD","IE00B3T34201.USD","IE00B19Z3581.USD","BK4578","BK4550","LU1934455194.USD","LU2324357040.USD","LU0320765992.SGD","LU0058720904.USD","SG9999015945.SGD","SG9999015986.USD","LU1023059063.AUD","LU1839511570.USD","LU0965508806.USD","LU1674673428.USD","LU0234570918.USD","LU1037948541.HKD","BK4139","LU0109394709.USD","LU0889565916.HKD","LU2112291526.USD","BK4568","BK4588","LU1934455863.HKD","LU0861579265.USD","LU1778281490.HKD","IE0002270589.USD","LU1430594728.SGD","LU0122379950.USD","LU2087621335.USD","LU1934455277.USD","SG9999015952.SGD","LU0114720955.EUR","LU1061106388.HKD","BK4566","LU1037948897.HKD","LU1571399168.USD","IE00BZ1G4Q59.USD","LU1057294990.SGD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU0965509010.AUD","LU2089984988.USD","LU0965509283.SGD","IE00BSNM7G36.USD","LU2468319806.SGD","LU0965509101.SGD","LU1066051498.USD","LU0882574055.USD","LU1674673691.USD","BK4532","LU0823416689.USD","BK4585","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":-0.0196},{"period":"3month","weight":-0.044},{"period":"6month","weight":-0.0178},{"period":"1year","weight":0.307},{"period":"ytd","weight":-0.0333}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}